# Modulation of premotor cortex response to sequence motor learning during escitalopramintake

Eóin N. Molloy<sup>1,2,3,4</sup>, Karsten Mueller<sup>2,5</sup>, Nathalie Beinhölzl<sup>1,3</sup>, Maria Blöchl<sup>2,3,8</sup>, Fabian A. Piecha<sup>1,3</sup>, André Pampel<sup>5</sup>, Christopher J. Steele<sup>3,12</sup>, Ulrike Scharrer<sup>1,3</sup>, Gergana Zheleva<sup>1,3</sup>, Ralf Regenthal<sup>9</sup>, Bernhard Sehm<sup>3,7,13</sup>, Vadim V. Nikulin<sup>3,6</sup>, Harald E. Möller<sup>2,5</sup>, Arno Villringer<sup>2,3,4,10,11</sup> & Julia Sacher<sup>1,2,3,10</sup>

Emotion & Neuroimaging Lab, Max Planck Institute for Human Cognitive and Brain Sciences<sup>1</sup>

International Max Planck Research School NeuroCom<sup>2</sup>

Dept. of Neurology, Max Planck Institute for Human Cognitive and Brain Sciences<sup>3</sup>

Faculty of Medicine, Leipzig University<sup>4</sup>

Nuclear Magnetic Resonance Unit, Max Planck Institute for Human Cognitive and Brain Sciences<sup>5</sup>

Centre for Cognition and Decision Making, Institute for Cognitive Neuroscience, National Research University Higher School of Economics<sup>6</sup>

Neuroplasticity & Motor Recovery Group, Max Planck Institute for Human Cognitive and Brain Sciences<sup>7</sup> Dept. of Psychology, University of Münster<sup>8</sup>

Division of Clinical Pharmacology, Rudolf-Boehm-Institute of Pharmacology and Toxicology, Leipzig University<sup>9</sup>

Clinic for Cognitive Neurology, Leipzig University<sup>10</sup>

Berlin School of Mind and Brain<sup>11</sup>

Dept. of Psychology, Concordia University<sup>12</sup>

Dept. of Neurology, Martin Luther University Halle-Wittenberg<sup>13</sup>

# **Abstract:**

The contribution of selective serotonin reuptake inhibitors (SSRIs) to motor learning by inducing motor cortical plasticity remains controversial given diverse findings from positive preclinical data to negative findings in recent clinical trials. To empirically address this translational disparity, we use functional magnetic resonance imaging (fMRI) in a double-blind, randomized controlled study powered to assess whether 20 mg escitalopram improves sequence-specific motor performance and modulates cortical motor response in 64 healthy female participants. We found decreased left premotor cortex responses during sequence-specific learning performance comparing single dose and steady escitalopram state. Escitalopram plasma-levels negatively correlated with the premotor cortex response. We did not find evidence in support of improved motor performance after a week of escitalopram-intake. These findings do not support the conclusion that 1-week escitalopram intake increases motor performance but could reflect early adaptive plasticity with improved neural processing underlying similar task performance when steady peripheral escitalopram levels are reached.

**Key words:** selective serotonin reuptake inhibitors, sequential motor learning, neural plasticity, functional MRI.

**Introduction:** 

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

Motor learning is the improved performance of a motor task following practice<sup>1</sup> and is modulated by monoaminergic transmission in cortical and subcortical motor networks<sup>2,3,4</sup>. Research on this monoaminergic basis of motor learning typically focuses on dopamine signaling in both health<sup>5,6</sup> and disease<sup>7</sup>. Evidence from rodents<sup>8</sup> and stroke patients<sup>9</sup>, however, suggests that serotonin also critically modulates motor behavior. Selective serotonin reuptake inhibitors (SSRIs), commonly prescribed medications for depression and anxiety disorders<sup>10</sup>, increase extracellular serotonin and successfully treat post-stroke depression<sup>11</sup>. In the absence of depressive symptoms, several studies have also demonstrated an effect of SSRIs on the recovery of post-stroke motor dysfunction<sup>12</sup>. Notably, the FLAME trial (Fluoxetine for Motor Recovery After Acute Ischemic Stroke<sup>9</sup>) showed approximately 50% motor recovery in 57 patients following combined fluoxetine treatment and physiotherapy, in a multi-center Randomized Controlled Trial (RCT). These findings were further supported by a meta-analysis of 52 RCTs in 4,060 patients, which, however, also acknowledged heterogeneity and methodological shortcomings in a substantial proportion of trials<sup>13</sup>. Possible mechanisms underlying SSRI modulation of motor performance and learning include antiinflammatory<sup>14,15</sup> and neurotrophic effects<sup>16</sup> such as increased neurogenesis<sup>17</sup>, proliferation<sup>18</sup>, protein expression enhancement<sup>19</sup>, upregulation of beta1-adrenergic receptors<sup>20</sup>, downregulation of GABA-transmission<sup>21,22</sup>, and hippocampal long-term potentiation<sup>23</sup>. These findings suggest that SSRIs may increase responsivity to environmental stimuli, possibly via changes in inhibitory and excitatory balance<sup>24</sup> and reorganization of cortical networks<sup>25-27</sup>. Studies in humans have provided support for this by demonstrating changes in resting state functional connectivity induced by a single dose of escitalopram<sup>28</sup>. Additionally, decreases in resting state alpha-frequency band induced by tryptophan depletion<sup>29</sup>, which are hypothesized to reflect alterations in the excitatory and inhibitory balance of cortical networks, have been observed in healthy volunteers. Moreover,

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

preliminary functional magnetic resonance imaging (fMRI) evidence has linked decreased functional responses in the motor network with improved motor performance following fluoxetine administration<sup>30-33</sup>. Recent large-scale RCTs in stroke patients such as the TALOS<sup>34</sup> and FOCUS trials<sup>35</sup>, involving over 642 and 3,000 patients, respectively, however, do not suggest beneficial effects of SSRIs on functional recovery. Critically, however<sup>36</sup>, these RCTs were conducted against the backdrop of routinely available rehabilitation and did not combine SSRI administration with a clearly defined motor learning paradigm, nor did they assess functional brain responses to SSRI intake. As a result, no previous study, either in healthy participants or in patients, has successfully leveraged prolonged training on an established motor learning paradigm in combination with SSRI-administration and fMRI in an adequately powered sample. Therefore, the hypothesis of whether SSRI administration, specifically in combination with an established motor learning paradigm, induces a beneficial effect on motor learning performance and changes the cortical motor response underlying the learning performance, remains to be tested empirically. The current study utilizes fMRI to address whether one week of SSRI administration in combination with a sequential motor learning task improves sequence specific motor performance and elicits changes in concurrent cortical motor response during task performance. In a doubleblind, randomized controlled pharmaco-fMRI study, we administered 20 mg (to reach 80% serotonin transporter (5-HTT) occupancy)<sup>37</sup> of escitalopram, the most 5-HTT selective and rapid onset SSRI<sup>38,39</sup> or placebo, to healthy females undergoing parallel fMRI assessment and training on a variant of the sequential pinch force task (SPFT)<sup>40</sup>. We chose a healthy homogeneous and voung sub-sample to avoid variance associated with pathology<sup>41,42</sup>, sex<sup>33</sup>, and age<sup>43</sup>. Our a priori hypotheses were (1) that one week of escitalopram intake would improve sequential motor

performance relative to placebo, as assessed by performance in a temporal lag condition on the SPFT, calculated as the time difference between a computer controlled visual stimulus and participant control of a pinch-force device. (2) By specifying this sequence-learning condition in an fMRI contrast (hereafter referred to as the learning contrast, i.e., the difference of functional brain responses between two experimental conditions comprising two levels of task difficulty), we also hypothesized escitalopram-induced changes in fMRI-response in core components of the motor network during task performance.

#### **Results:**

58

59


60

61

62

63

Following a baseline condition, participants were randomized to receive either 20 mg of escitalopram or placebo (mannitol/aerosol) orally for 7 days. Sequence-specific motor training was conducted 5 times; baseline, on days 1 (single dose), 5 and 6, and 7 (steady state) of escitalopram administration. Functional MRI data were acquired at 3 concurrent time points: baseline, single dose, and steady state (Figure 1).



**Figure 1. Study design and task:** Following baseline, escitalopram or placebo administration took place for 7 consecutive days. Post baseline, motor training took place at single dose (first day), days 5 and 6, and at steady state (day 7). Motor training on days 5 and 6 was completed outside the scanner. fMRI data were acquired at baseline, single dose, and steady state. Task = Sequential Pinch Force Task, fMRI = Functional Magnetic Resonance Imaging, Force = the yellow bar controlled by the participants, the rise and fall of which was required to match the rise and fall of the blue (reference bar, i.e., the bar controlled by a computer).

#### **Demographics:**

65

- No differences were observed between groups in any baseline screening measures. Escitalopram
- 67 levels were within the expected range<sup>44</sup> (Table 1).

**Table 1. Demographic overview:** Group demographic overview and mean single dose and steady state escitalopram plasma concentrations. Group values refer to mean $\pm$ standard deviation. Demographic values rounded to the nearest whole number. Escit. = escitalopram, ASEC = antidepressant side effect checklist-score, kg/m<sup>2</sup> = kilogram force per square meter, u/l = units per liter, ng/ml = nanograms/milliliters.

	Escitalopram (n=31)	Placebo (n=33)	<i>t</i> -value	<i>p</i> -value
Age (years)	$24 \pm 3$	$23 \pm 4$	-0.3	0.74
BMI $(kg/m^2)$	$22 \pm 2$	$21 \pm 2$	-1.3	0.19
Lutropin (u/l)	$2 \pm 2$	$1 \pm 2$	-1.2	0.20
Follitropin (u/l)	$3\pm3$	$2 \pm 3$	-1.3	0.19
ASEC single dose	3±3	1±1	3.9	$\leq 0.001$
ASEC steady state	1±2	1±1	-0.7	0.48
Escit. single dose (ng/ml)	$20 \pm 5$	-	-	-
Escit. steady state (ng/ml)	$46 \pm 11$	-	-	-

# **Sequence-specific motor learning:**

68

69


70

71

72

- We did not find any significant differences between the escitalopram and placebo groups on
- behavioral measures of sequence-specific motor learning:
- 75 (1) Group comparisons of mean performance at baseline did not show any significant group
- 76 differences in sequence-specific motor learning behavior (t=-0.25, p=0.80).
- 77 (2) For group comparisons over time, a mixed effects model including a fixed effect of *time* fit the
- data significantly better than a random-intercept only model, reflecting a decrease in lag scores
- 79 (Table 2). The fixed effect of group and the interaction of time and group did not show a significant
- 80 improvement in fit, demonstrating that, while both groups improved in sequence-specific motor
- 81 performance over time, they did so comparably (Figure 2).
- 82 (3) Post-hoc two-sample t-tests did not show a significant group difference in mean performance
- at either single dose or steady state. Comparisons of the delta scores from baseline to steady state
- 84 did not show any significant differences between groups. Bayes Factor analysis of group
  - comparisons at single dose and steady, as well as the delta, yields moderate evidence in support of
- the null hypothesis (Table 2).
- 87 (4) Additionally, correlation analyses did not show an association between total ASEC scores with
- mean behavioral lag scores at either single dose (r=-0.03, p=0.8,) or at steady state (r=0.11 p=0.37),
- 89 respectively.

85



**Figure 2. Sequential motor learning: Left:** Significant improvements in lag scores over 5 days of sequential motor training across both escitalopram and placebo. However, despite a significant learning effect, we observed no significant group differences in performance, nor did we observe an interaction effect. **Right:** Comparison of the rate of change between baseline and steady state yield no significant group differences. Bold fonts indicate training completed in the scanner.

**Table 2. Comparisons of nested linear mixed effects models and post-hoc testing for sequence-specific lag scores:** Model comparisons for computing the omnibus tests for *group* and *time* as well as their interaction effect for both outcome measures.  $\chi 2$  and respective *p*-values were computed from LRT between nested models with results of independent samples *t*-tests and corresponding Bayes Factors on mean single dose, steady state, and absolute rate of improvement scores (deltas). BF<sub>01</sub> = Bayes Factor indicating the likelihood of the alternative hypothesis compared to the null hypothesis. M±SD = means±standard deviation, LRT = likelihood ratio test, df = degrees of freedom,  $\chi 2$  = Chi-square. \*Significant improvement in model fit.

Mixed Effects Modelling	Fixed Effects	Random effects	LRT		Marginal R <sup>2</sup>	
			$\chi^2$ (df)	<i>p</i> -value	_	
Intercept	-	Subject	-	-	0	
Time	time	Subject	3301.3 (24)	≤0.001*	0.2917	
Group	group+time	Subject	0.0181 (1)	0.8931	0.2918	
Interaction	group*time	Subject	25.722 (24)	0.3674	0.2934	
Post-hoc Testing	Escitalopram M±SD	Placebo M±SD	<i>t</i> -value (df)	<i>p</i> -value	Cohen's d/BF <sub>01</sub>	
Single dose	99.8±57.9	95.1±67.8	-0.3 (62)	0.76	-0.07/0.26	
Steady state	58.1±36.1	63.8±44.1	0.56 (62)	0.57	0.14/0.29	
Delta scores	-107.1±56.6	-96.7±59.2	0.71 (62)	0.47	0.18/0.31	

#### **Functional MRI responses during sequence-specific motor learning:**

(1) We did not observe any group differences in the learning contrast fMRI responses at baseline.

(2) Within the escitalopram group, we found a significant decrease of the learning contrast in bilateral motor regions (Figure 3, escitalopram panel, blue overlay) when comparing single dose with steady state. We did not observe any significant increases in whole-brain fMRI signal for this learning contrast.

(3) Comparisons of groups over time reveals decreases in the learning contrast in the left premotor cortex of the escitalopram group between single dose and steady state that are not observed in placebo (Figure 3, interaction panel, yellow overlay). A sensitivity analysis controlling for intrasubject variance in task performance replicates this result, showing a significant *group* by *time* interaction with a decrease in the learning contrast from single dose to steady state in the escitalopram group in the left premotor cortex (Table 3).

(4) One-sample *t*-tests across the learning contrast images in each group at each time point show bilateral activation in both the escitalopram and placebo groups at each of baseline, single dose, and steady state (Figure 3).




Figure 3. Escitalopram-induced decreases in motor responses during sequential motor learning: Group dependent changes in the learning contrast over time. Mean functional group response of the escitalopram group (top) and placebo (bottom) at each baseline, single dose, and steady state measurements are shown in red. Single Dose>Steady State: Brain regions in the escitalopram group with significant decreases in the learning contrast (blue) between single dose and steady state (top) show decreases in bilateral premotor and temporal-parietal regions (Table 3). Comparisons between single dose with steady state in the placebo group yield no significant changes (bottom). Interaction: Comparisons of groups over time show decreases in the learning contrast signal in the left premotor cortex of the escitalopram group that are not observed in placebo (violet). Consideration of behavioral performance as a variable of interest shows brain regions where changes in the learning contrast positively correlate with improvement in motor performance, also with a peak in the left premotor cortex (overlaid in yellow). All results are shown with p < 0.05 family-wise error (FWE) correction at a cluster forming threshold of p < 0.001. All orthogonal planes presented are the same. β = beta value at global maximum coordinate.

Table 3. Escitalopram-induced motor network changes in the learning contrast during sequence motor learning: Results of a paired comparison of single dose and steady state within the escitalopram group and subsequent interaction comparisons with placebo. All results obtained with a  $2\times2$  flexible factorial design. T=t-values, Z=t-values, Z=t-v

Brain Region	p(FWE-corr)	Cluster Extent	T	Z	MNI (x,y,z)
Escit. Paired					
Left Premotor					
Cortex	< 0.001	913	6.33	5.50	-18, 11,59
			6.25	5.44	-21, 11, 50
			6.17	5.39	-27, 8, 59
Right Premotor					
Cortex	< 0.001	233	6.15	5.38	30, -4, 41
			5.10	4.62	24, -4, 65
			4.28	3.97	30, 2, 62
Left Superior					
Parietal Lobule	< 0.001	260	5.82	5.14	-39, -46, 53
			5.33	4.79	-33, -43, 32
			5.13	4.64	-36, -46, 41
Left Middle					
Temporal Gyrus	0.025	97	4.97	4.52	-48, -58, -4
			3.33	3.17	-39, -67, 8
Left Superior					
Frontal Gyrus	< 0.001	295	4.87	4.44	-18, 35, 38
			4.53	4.17	-18, 44, 20
			4.31	4.00	-15, 56, 26
Right Superior					
Parietal Lobule	< 0.001	257	4.74	4.34	12, -61, 62
			4.23	3.93	18, -61, 50
			4.06	3.79	33, -40, 59
Left Postcentral					
Gyrus	< 0.001	215	4.70	4.30	-9, -46, 74
			4.67	4.28	-12, 52, 65
			3.63	3.44	-15, -70, 50
Right Middle					
Temporal Gyrus	0.002	172	4.67	4.29	42, -58, 11
			3.77	3.55	33, -58, 23
			3.68	3.47	27, -76, 11
Interaction					
Left Premotor					
Cortex	0.044	82	4.36	4.04	-21, 11, 50
			4.17	3.88	-15, 8, 59
			4.10	3.82	-18, -4, 59
Interaction (Sensitivity)					
Left Premotor					
Cortex	0.017	111	4.68	4.29	-21, 11, 50
COLUA	0.017	111	4.26	3.95	-15, 8, 59
			4.20		-13, 8, 39
			4.07	3.80	-21, 3, 30

(5) Correlation analysis between the change in sequence-specific learning performance with the fMRI signal change in the learning contrast from single dose to steady state within the escitalopram group reveals a significant positive correlation in brain regions including the left premotor cortex (Figure 4; yellow overlay, Supplementary Table 3).
(6) Correlational analysis between escitalopram plasma levels and the learning contrast in the escitalopram group shows a significant negative correlation, with increases in escitalopram plasma concentration associated with decreases in the learning contrast in the left supplementary motor area and supramarginal gyrus (Figure 4, Supplementary Table 4).




Figure 4: Correlations between escitalopram plasma levels and cortical premotor response during sequence-specific learning from single dose to steady state: (A) Escitalopram plasma concentrations negatively correlate with changes in the learning contrast in bilateral cortical motor regions, including the premotor cortex (premotor cortex from significant  $2\times2$  interaction overlaid in yellow), with a peak in the left supramarginal gyrus. (B) Betas containing parameter estimates for error from the left premotor cortex plotted against escitalopram plasma levels at single dose and steady state, respectively. Results refer to the sequence-specific learning contrast and are shown with p<0.05 family-wise error (FWE) correction at a cluster forming threshold of p<0.001. Escit. = escitalopram, ng/ml = nanograms/milliliters.  $\beta$  = beta value at premotor MNI coordinates.

#### **Analysis of mature BDNF levels:**

Analysis of mBDNF levels from baseline to steady state in both groups combined does not reveal any significant changes over time (F(1, 62) = 2.195, p=0.12), and paired t-tests do not indicate significant changes from baseline to steady state in either the escitalopram (t = -1.23, p=0.22) or placebo group (t =-1.5, p=0.14), respectively.

**Discussion:** 

In this randomized controlled interventional study, we investigated whether administration of 20 mg escitalopram improves motor learning performance and alters functional brain response in the motor network during sequence motor learning. Results show a significant learning effect in sequence-specific motor performance though this rate of improvement does not differ between groups. Additionally, we do not observe any significant group differences at any time point, or in rate of improvement. With fMRI, we find significant escitalopram-induced decreases in the left cortical premotor response during sequence-specific learning comparing single dose and steady levels of escitalopram. Moreover, consideration of behavioral performance as a variable of interest during this phase of learning reveals that these changes in the sequence-specific learning contrast positively correlate with improvement in motor performance. Finally, we observe a negative correlation between escitalopram-plasma levels and the fMRI response during the sequence-specific learning contrast in the left premotor cortex during task-performance, suggesting a parallel development between escitalopram plasma kinetics and the attenuation of cortical motor response to sequence-specific motor learning.

The lack of an effect of SSRI-administration on motor learning performance differs from previous findings in healthy vounteers<sup>31-33</sup>. These studies, however, were neither powered nor pre-registered to test this as an *a-priori* hypothesis, with six healthy volunteers for five different behavioral tests and one fMRI experiment<sup>31,32</sup> and nineteen volunteers for six different behavioral assessments<sup>33</sup>. Additionally, we administered escitalopram, and chose a task that may be less cognitively demanding due to repetitive isotonic contractions<sup>45</sup>, possibly creating earlier ceiling effects in healthy adults. These previous findings could be specific to paroxetine, require tasks with more spatial and coordination-oriented sensorimotor components, or may only become apparent after several weeks of administration. Nevertheless, given that we administered the SSRI with the

highest transporter selectivity<sup>46</sup>, employed a task that reliably measures sequence motor learning<sup>40</sup>, and tested a well-powered sample, it is unlikely that this discrepancy is due to the choice of SSRI or motor paradigm alone. Furthermore, our exploratory analysis of mature BDNF levels in plasma did not reveal any significant changes associated with improved motor learning performance in either group. While this is consistent with findings of improved motor performance in healthy volunteers to be unrelated to peripheral BDNF levels<sup>47</sup>, evidence supportive of an association between motor skill learning and increased BDNF levels have also been reported<sup>48</sup>. While future studies should assess potential SSRI modulation of motor learning with additional paradigms, our results do not support a beneficial effect of SSRI-administration on motor learning performance in health.

We do report evidence supportive of our second hypothesis however, with significant decreases in functional responses in left premotor cortex during sequence specific motor learning, relative to placebo (Figure 3). While both increases and decreases in functional brain responses underlie motor learning<sup>49</sup>, this pattern is dependent on differential stages of learning and is defined by multiple parallel processes<sup>50-52</sup>. Early fast learning is accompanied by rapid improvements in performance, followed by slow learning that characterizes a more consolidatory phase<sup>53,54</sup>. Patterns of functional responses observed during this phase are also influenced by the type of task, with explicit learning of repetitive and unchanging sequences hypothesized to lead to faster automation of performance<sup>51,55,56</sup> and a subsequent reduction in cognitive load needed for task completion. Given the predictable repetition of the learning sequence on our task and the timing of our assessments, it is possible that the observed escitalopram-induced decreases in the learning contrast reflect this automation of responses and subsequent consolidation of sequence learning.

Such a neural consolidation process in response to 1 week of escitalopram-intake is consistent with

## Running Head: Premotor cortex response to motor learning during escitalopram-intake

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

a recent conceptual model of SSRI influences on post-stroke recovery<sup>57</sup>. The authors propose that acute SSRI exposure changes the excitatory and inhibitory balance with increases in excitatory signaling, allowing for the remodeling of cortical pathways<sup>57</sup>. Subsequent SSRI exposure leads to a reset in homeostasis with a heightening of γ-aminobutyric acid (GABA) tone<sup>57</sup>, allowing for remodeled pathways to become engrained as task performance continues. Further support for this interpretation stems from studies identifying an inverse relationship between cortical GABA concentrations and functional brain responses<sup>58,59</sup> and SSRI administration has been shown to increase cortical GABA levels in rodents<sup>60</sup> and healthy volunteers<sup>61</sup>. Finally, the observation that the escitalopram-induced decrease in the learning contrast is negatively associated with escitalopram kinetics occurs in a timeframe consistent with that typically required for 5-HT<sub>1A</sub> autoreceptor desensitization<sup>62</sup>, which could also modulate effective enhancement of cortical GABAergic tone<sup>63</sup>. In summary, it is possible that this escitalopram-induced decrease in premotor response in the learning contrast reflects more effective neural task processing, relative to placebo, in a region central to temporally and visually-oriented motor learning and planning<sup>64-67</sup>. This interpretation is consistent with the hypothesis of an SSRI-induced window of experiencedependent plasticity as an attenuator of neural efficiency during performance<sup>25,26</sup>. An alternative explanation of this finding is a habituation effect of neural responses during repetitive sequence-specific motor learning that may be emphasized by escitalopram administration. While we report a significant three-way interaction for brain, task, and group (Figure 4), this effect is limited to the comparison between a single dose and steady state and in the escitalopram group only, despite the observation that both groups successfully improve performance over time. It is possible that the neural responses during task performance in the placebo group reflects a simpler order effect, whereby neural responses adapt incrementally, rather

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

than via an adaptive plasticity mechanism. Integration of more direct measures of cortical excitation and inhibition can allow for more fine-grained investigations into acute and subacute SSRI-effects.

Nevertheless, there are some limitations to consider when interpreting these results. We acknowledge that the initial strong learning effect may have masked more subtle modulation of performance with escitalopram at a later training session. Though a known limitation of this task, we chose the SPFT for this well-established and reliable learning effect. While performance reaches a ceiling during the fourth and fifth sessions, as described previously<sup>40</sup>, we still observe a considerable change in performance after the administration of the single dose and subsequent training sessions, thus maintaining the falsifiability of our primary hypothesis. Second, our results may not generalize to males or older adults as our sub-sample consists only of females with standardized downregulation of ovarian hormones. This was a deliberate a-priori restriction to eliminate confounds such as sex-differences<sup>33</sup> and fluctuating endogenous hormones<sup>68</sup> on environmental learning and escitalopram responsivity. Third, other studies have gradually increased escitalopram doses for pharmaco-fMRI protocols in healthy participants<sup>69</sup> to minimize adverse effects. We chose a fixed dose of 20 mg to reliably block 80 % of 5-HTT<sup>37</sup>, an approach previously well tolerated<sup>28</sup>. While four participants discontinued protocol because of adverse effects in the escitalopram group, this was also the case for two placebo participants, and there was no group difference in self-reported side effects at steady state. Finally, fMRI provides an indirect measure of neural activity, which is susceptible to non-neural changes such as vascular uncoupling. Given the functional specificity of the premotor cortex, it is unlikely that these findings are solely driven by changes in global blood flow. We cannot, however, identify underlying molecular mechanisms, which require quantitative measures such as MR-spectroscopy measures of GABA

and glutamate or [<sup>11</sup>C]UCB-J positron emission tomography, a recently developed technique for *in vivo* imaging of synaptic plasticity<sup>70,71</sup>.

In conclusion, this is the first study to investigate the effect of steady escitalopram administration on motor learning in an established sequential motor learning paradigm and the associated brain response in a sufficiently powered sample. In this pre-registered, randomized, controlled, interventional study, we do not find evidence in support of improved performance in response to 1 week of escitalopram-intake during sequence-specific motor training. A major difference we observe between groups is a decrease in premotor cortical responses during sequence-specific learning performance contrasting single dose and steady drug state. Considering previous findings on sequential motor learning and associated neural correlates in the motor network, less premotor response during similar performance may suggest more effective neural processing and greater consolidation of performance<sup>64</sup>. By combining escitalopram administration and sequence-specific motor training for one week, we provide the first empirically tested framework for assessing SSRI-effects on human adaptive motor plasticity in health. Our paradigm and findings may help disentangle the seemingly contradictory results between preclinical models and recent clinical trials and represent an important milestone towards understanding the role of SSRIs in human motor learning.

# **Materials and methods:**

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

Participants & eligibility:

The study was designed to have statistical power of 95% to detect a significant effect of escitalopram on sequence motor learning, assuming a small effect size (d = 0.20) and an  $\alpha$ -level of <0.05. A power analysis conducted using G\*Power (v.3.1.9.2)<sup>72</sup> suggested a minimum sample size of 56. Eligible individuals were right-handed, aged 18–35 years, with a body mass index (BMI) 18.5-25 kg/m<sup>2</sup>, without history of neurological or psychiatric illness, and female on oral contraceptives for ≤3 months<sup>73,74</sup> to eliminate sex and hormone-dependent escitalopram responsivity<sup>75</sup>. Exclusion criteria were medication use, contraindications for MRI, tobacco use, alcohol abuse, positive drug or pregnancy tests, professional musicianship and athleticism, and abnormal QT times in electrocardiogram screenings. In total, 88 participants were screened with 71 enrolled. Analyses included 64 volunteers for the behavioral analysis as 6 (escitalogram=4) chose to discontinue participation and n=1 (placebo) was excluded due to a pre-analytical error in plasma sample acquisition. Sixty volunteers were included in functional imaging analysis as 4 were excluded due to MRI data quality concerns (2 escitalopram) due to head movement. 1 volunteer from the placebo group was excluded due to an artefact in an anatomical sequence and 1 participant from the escitalopram group was excluded due to an artefact detected during acquisition of the functional sequence (Supplementary Figure 1).

#### **Study design and procedure:**

The Ethics committee of the Faculty of Medicine, Leipzig University approved all procedures (approval number 390/16-ek) and the study was pre-registered at clinicaltrials.gov (ID: NCT03162185). Participants were randomized to receive either 20 mg of escitalopram or placebo (mannitol/aerosol) orally for 7 days. Randomization was performed by the Central Pharmacy of Leipzig University with equal condition allocation. Sequential motor training was conducted 5 times (baseline, on day 1 of escitalopram administration, days 5 and 6 of drug administration, and

at steady state – after 7 days). Functional magnetic resonance imaging data (fMRI) and serum mature brain-derived neurotrophic factor (mBDNF) samples were acquired at baseline, single dose, and steady state. Electrocardiogram recordings were conducted at single dose, day 4, and steady state to monitor potential changes in QT intervals. Adverse reactions to escitalopram were recorded using the antidepressant side-effects checklist (ASEC)<sup>76</sup>. All participants remained under medical supervision during the experiment. Concentrations of escitalopram in plasma was assessed chromatographically using a quality control sample. Deviation of the measured escitalopram concentration of the sample was tested for an acceptance interval of  $\pm 15\%$ . All behavioral and fMRI assessments took place 3 hours after escitalopram or placebo intake to allow for escitalopram to reach maximum levels in serum<sup>44</sup>.

# **Sequential pinch force task:**

We assessed sequence motor learning using a variant of the sequential pinch force task (SPFT), with Presentation (v16.5) running on WindowsXP. Baseline, single dose, and steady state measurements took place during fMRI, while day 5 and day 6 were conducted outside the scanner on an identical separate device. Task completion involved controlling the rise and fall of a yellow bar (force) via the participant's thumb and index finger (attenuated to individual strength) while attempting to match the speed of a moving computer controlled blue reference bar (Figure 1). We measured performance in two conditions: (1) a control condition, where the reference bar moves sinusoidally and (2) a sequence-specific learning condition, in which the reference moves in a sequential pattern that remains stable across sessions. A rest condition punctuated training to avoid fatigue. Each session consisted of 5 blocks with 3 trials per block and cycled through simple, rest, and learning. Participants received no feedback regarding performance. To assess performance, we calculated the time difference (lag) in milliseconds between the reference and force bar during the learning trials.

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

Demographic data analysis: Independent samples t-tests using the R statistical programming language<sup>77</sup> tested for potential group differences in age, BMI, downregulated hormonal profile, and on total ASEC scores at single dose and steady state. Behavioral data preprocessing: All SPFT data were preprocessed using in house Matlab scripts. Quality control used an outlier labeling approach<sup>78</sup> implemented in Python (v2.7.15) in which trial, condition, group, and outcome specific interquartile ranges were multiplied by a factor of 1.5 to compute upper and lower bound thresholds. Behavioral data analysis: All behavioral data analyses were conducted using R. (1) Independent samples t-tests assessed baseline group differences using the 't.test' function to assess efficacy of randomization. (2) Comparisons between groups over time employed an omnibus linear random-intercept mixed effect modeling approach using the 'lmer' function, within the 'lme4' package in R (independent factors: group, time, dependent variable: lag). Contributions of each fixed effects were assessed with a likelihood ratio test for improvement of model fit. (3) Post-hoc independent samples t-tests were conducted on mean single dose and steady state scores to assess potential group differences at each critical time point of escitalopramadministration. Additionally, the delta (difference between mean performance at steady state compared to baseline) was compared between groups for each outcome via independent samples

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

t-tests. Bayes Factor t-tests using the 'ttestBF' function in the 'BayesFactor' package assessed the likelihood of the null hypothesis for all independent sample analyses. (4) Pearson's correlation analyses assessed potential associations between total ASEC scores and mean lag performance at both single dose and steady state. fMRI data acquisition: fMRI data were acquired with gradient-echo echo planar imaging (EPI) on a 3-Tesla MAGNETOM Verio scanner (Siemens, Erlangen, Germany, 32-channel head-coil, flip angle 90°, TR=2000 ms, TE=30 ms, field of view=192×192 mm<sup>2</sup>, 30 slices, 64×64 matrix, 3×3×3mm<sup>3</sup> nominal resolution, 495 volumes, aligned -15° along the anterior to posterior commissure, ~16 minutes). A wholebrain three dimensional T1-weighted Magnetization Prepared Rapid Gradient-echo (MPRAGE) was also acquired at each time point for co-registration <sup>79</sup> with inversion time, TI=900 ms, TR=2300 ms, TE=2.98 ms,  $1\times1\times1$ mm<sup>3</sup> nominal isotropic resolution, ~9 minutes<sup>80</sup>. fMRI data analysis – Preprocessing and first-level analysis: Data pre-processing was conducted using SPM12 (v12.7219). Data were realigned, unwarped, normalized to Montréal Neurological Institute (MNI) space, and smoothed with a Gaussian kernel (8mm at full-width-half-maximum). First level analysis was performed for baseline, single dose and steady state separately using a general linear model (GLM) including all three experimental conditions: learning, simple, and rest. In addition, each analysis contained head-movement parameters obtained during preprocessing motion correction. Following parameter estimation, we generated contrast images specific to sequence learning by specifying the learning contrast (i.e., the difference between the learning and simple conditions).

fMRI data analysis – Group-level analysis:

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

Using contrast images obtained at the first level, second level analyses were performed with SPM12 in Matlab (v9.7). Results were considered statistically significant at a cluster-defining threshold of p<0.001 corrected at p<0.05 using family-wise error (FWE) for multiple comparisons at the cluster-level. (1) An independent-samples t-test assessed potential differences in the learning contrast between groups at baseline. (2) Following baseline comparisons, we assessed changes across time within the escitalopram group. Using a paired t-test, we each compared baseline to single dose, baseline to steady state, and single dose to steady state. Both directions of each t-statistic were assessed to test for both increases and decreases in fMRI response during the learning contrast over time. (3) To investigate group differences with respect to results obtained in analyses (2), we specified a flexible factorial model using factors for *subject* (for repeated measurements), *time* and *group*. Comparisons from (2) yielding a significant difference were repeated within this model to validate results from paired t-tests. Within this model, we tested for an interaction between group and time. Additionally, a sensitivity analysis repeated this interaction analysis with an additional regressor. Two mean behavioral measures for each participant (one for each timepoint) were entered as nuisance covariates in the GLM<sup>81</sup>. For these behavioral measures, we used the behavioral sequence-specific learning measure "lag learning-simple score" (LLSS), as calculated for each participant by subtracting the mean simple condition scores from the mean learning condition lag scores.

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

(4) To visualize mean signal for the learning contrast for each group at baseline, single dose, and steady state, a series of one-sample t-tests was conducted on each group at each timepoint separately. (5) In order to test for a correlation between motor performance improvement and change in the learning contrast within the escitalopram group, we used the LLSS as an effect of interest within a second flexible factorial design<sup>81</sup>. Here, the model was generated using the factors *subject*, *group*, and LLSS. (6) With the aim of testing for a correlation between escitalopram plasma and brain kinetics during the learning contrast, escitalopram plasma levels were entered as an effect of interest within a third flexible factorial design<sup>81</sup>, within the escitalopram group, using the factors *subject*, *group*, and plasma escitalopram levels. **Analysis of serum mature BDNF levels:** A one-way repeated measures ANOVA was implemented in R using the 'Anova' function to assess changes in serum mBDNF levels across time. Paired samples t-tests in both the escitalopram and placebo groups compared baseline to steady state within each group, separately.

# **Acknowledgements:**

We thank Heike Schmidt-Duderstedt and Kerstin Flake for assisting with preparation of the figures and Dr. Kristin Ihle for her assistance with medical supervision of all participants during the experiments.

# **Competing Interests:**

The authors declare that no competing interests exist.

# **Funding:**

This research was supported by the FAZIT Foundation to ENM and The Branco Weiss Fellowship

i

- Society in Science to JS and the Max Planck Society.

#### **References:**

- 1. Diedrichsen, J., Kornysheva, K. (2015). Motor skill learning between selection and execution. *Trends Cogn Sci.* 19(4):227-33. doi: 10.1016/j.tics.2015.02.003.
- 2. Molina-Luna K., Pekanovic, A., Röhrich, S., Hertler, B., Schubring-Giese, M., Rioult-Pedotti, MS., Luft, A.R. (2009). Dopamine in motor cortex is necessary for skill learning and synaptic plasticity. *PLoS One.* 17;4(9):e7082. doi:10.1371/journal.pone.0007082.
- 3. Rioult-Pedotti, MS., Pekanovic, A., Atiemo, CO., Marshall, J., Luft, AR. (2015). Dopamine Promotes Motor Cortex Plasticity and Motor Skill Learning via PLC Activation. *PLoS One*. 10(5):e0124986. doi: 10.1371/journal.pone.0124986.
- 4. Vitrac, C., Benoit-Marand, M. (2017) Monoaminergic Modulation of Motor Cortex Function. *Front. Neural Circuits* 11:72. doi: 10.3389/fncir.2017.00072.
- 5. Flöel, A., Breitenstein, C., Hummel, F., Celnik, P., Gingert, C., Sawaki, L., Knecht, S., Cohen, LG. (2005). Dopaminergic influences on formation of a motor memory. *Ann Neurol.* 58(1):121-30. doi:10.1002/ana.20536.
- 6. Flöel, A., Garraux, G., Xu, B., Breitenstein, C., Knecht, S., Herscovitch, P., Cohen, LG. (2008). Levodopa increases memory encoding and dopamine release in the striatum in the elderly. *Neurobiol Aging*. 29(2):267-79. doi:10.1016/j.neurobiolaging.2006.10.009
- 7. Magrinelli, F., Picelli, A., Tocco, P., Federico, A., Roncari, L., Smania, N., Zanette, G., Tamburin, S. (2016). Pathophysiology of Motor Dysfunction in Parkinson's Disease as the Rationale for Drug Treatment and Rehabilitation. *Parkinsons Dis.* doi:10.1155/2016/9832839
- 8. Maya Vetencourt, JF., Sale, A., Viegi, A., Baroncelli, L., De Pasquale, R., O'Leary, OF., Castrén, E., Maffei, L. (2008). The antidepressant fluoxetine restores plasticity in the adult visual cortex. *Science*, 320(5874), 385-388. doi:10.1126/science.1150516.
- 9. Chollet, F., Tardy, J., Albucher, JF., Thalamas, C., Berard, E., Lamy, C., Bejot, Y., Deltour, S., Jaillard, A., Niclot, P., Guillon, B., Moulin, T., Marque, P., Pariente J, Arnaud, C. Loubinoux, I. (2011). Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. *Lancet Neurol*, 10(2), 123-130. doi:10.1016/S1474-4422(10)70314-8.
- 10. Cipriani, A., Furukawa, TA., Salanti, G., Chaimani, A., Atkinson, LZ., Ogawa, Y., Leucht, S., Ruhe, HG., Turner, EH., Higgins, JPT., Egger, M., Takeshima, N., Hayasaka, Y., Imai, H., Shinohara, K., Tajika, A., Ioannidis, JPA., Geddes, JR. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. *Lancet*. 7;391(10128):1357-1366. doi: 10.1016/S0140-6736(17)32802-7.
- 11. Hackett, ML., Anderson, CS., House, A., Halteh, C. (2006). Interventions for preventing depression after stroke. *Cochrane Database Syst Rev.* 16;(3):CD003689. doi: 10.1002/14651858.CD003689.pub3.

- 12. Acler, M., Robol, E., Fiaschi, A., Manganotti, P. (2009). A double blind placebo RCT to investigate the effects of serotonergic modulation on brain excitability and motor recovery in stroke patients. *Journal of Neurology* 256(7):1152-8. doi: 10.1007/s00415-009-5093-7.
- 13. Mead, GE., Hsieh, CF., Hackett, M. (2013). Selective serotonin reuptake inhibitors for stroke recovery. *JAMA*. 310(10):1066-7. doi: 10.1001/jama.2013.107828.
- 14. Lim, CM., Kim, SW., Park, JY., Kim, C., Yoon, SH., Lee, JK. (2009). Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect. *J Neurosci Res.* 87(4):1037-45. doi: 10.1002/jnr.21899.
- 15. Tynan, RJ., Weidenhofer, J., Hinwood, M., Cairns, MJ., Day, TA., Walker, FR. (2012). A comparative examination of the anti-inflammatory effects of SSRI and SNRI antidepressants on LPS stimulated microglia. *Brain Behav Immun.* 26(3):469-79. doi: 10.1016/j.bbi.2011.12.011.
- 16. Schmidt, HD., Duman, RS. (2007). The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. *Behav Pharmacol.* 18(5-6):391-418. doi: 10.1097/FBP.0b013e3282ee2aa8
- 17. Malberg, JE., Eisch, AJ., Nestler, EJ., Duman, RS. (2000). Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. *J Neurosci*. 15;20(24):9104-10. doi: https://doi.org/10.1523/JNEUROSCI.20-24-09104.2000.
- 18. Lyons, L., ElBeltagy, M., Umka, J., Markwick, R., Startin, C., Bennett, G., Wigmore, P. (2011). Fluoxetine reverses the memory impairment and reduction in proliferation and survival of hippocampal cells caused by methotrexate chemotherapy. *Psychopharmacology (Berl)*. 215(1):105-15. doi: 10.1007/s00213-010-2122-2.
- 19. Cooke, JD., Grover, LM., Spangler, PR. (2009). Venlafaxine treatment stimulates expression of brain-derived neurotrophic factor protein in frontal cortex and inhibits long-term potentiation in hippocampus. *Neuroscience*. 162(4):1411-9. doi: 10.1016/j.neuroscience.2009.05.037.
- 20. Pälvimäki, EP., Laakso, A., Kuoppamäki, M., Syvälahti, E., Hietala, J. (1994). Upregulation of β1-adrenergic receptors in rat brain after chronic citalopram and fluoxetine treatments. *Psychopharmacology*. 115: 543. https://doi.org/10.1007/BF02245579
- 21. Yan, Z. (2002). Regulation of GABAergic inhibition by serotonin signalling in prefrontal cortex. *Molecular Neurobiology* 26(2-3) 203-216. doi: 10.1385/MN:26:2-3:203
- 22. Choi, HC., Kim, YI., Song, HK., Kim, JE., Kim, DS., Kang, TC. (2010). Effects of selective serotonin reuptake inhibitors on GABAergic inhibition in the hippocampus of normal and pilocarpine induced epileptic rats. *Brain Res.* 1357:131-41. doi: 10.1016/j.brainres.2010.08.010.

- 23. Mlinar, B., Stocca, G., Corradetti, R. (2015). Endogenous serotonin facilitates hippocampal long-term potentiation at CA3/CA1 synapses. *J Neural Transm(Vienna)*. 122(2):177-85. doi: 10.1007/s00702-014-1246-7.
- 24. Batsikadze, G., Paulus, W., Kuo, MF., Nitsche, MA. (2013). Effect of serotonin on paired associative stimulation-induced plasticity in the human motor cortex. *Neuropsychopharmacology*, 38(11), 2260-2267. doi:10.1038/npp.2013.127.
- 25. Castrén, E. (2005). Is mood chemistry? *Nat Rev Neurosci*, 6(3), 241-246. doi:10.1038/nrn1629
- 26. Castrén, E. (2013). Neuronal network plasticity and recovery from depression. *JAMA Psychiatry*, 70(9), 983-989. doi:10.1001/jamapsychiatry.2013.1
- 27. Siepmann, T., Penzlin, A.I., Kepplinger, J., Illigens, BM., Weidner, K., Reichmann, H., Barlinn, K. (2015). Selective serotonin reuptake inhibitors to improve outcome in acute ischemic stroke: possible mechanisms and clinical evidence. *Brain Behav*. 23;5(10): e00373. doi: 10.1002/brb3.373.
- 28. Schaefer, A., Burmann, I., Regenthal, R., Arélin, K., Barth, C., Pampel, A., Villringer, A., Margulies, DS., Sacher, J. (2014). Serotonergic modulation of intrinsic functional connectivity. *Current Biology*, 24(19), 2314-2318. doi: 10.1016/j.cub.2014.08.024.
- 29. Knott, VJ., Howson, AL., Perugini, M., Ravindran, AV., & Young, SN. (1999). The Effect of Acute Tryptophan Depletion and Fenfluramine on Quantitative EEG and Mood in Healthy Male Subjects. *Biological Psychiatry*; (46) 229–238.
- 30. Loubinoux, I., Boulanouar, K., Ranjeva, JP., Carel, C., Berry, I., Rascol, O., Celsis, P., Chollet, F. (1999). Cerebral functional magnetic resonance imaging activation modulated by a single dose of the monoamine neurotransmission enhancers fluoxetine and fenozolone during hand sensorimotor tasks. *J Cereb Blood Flow Metab*. 19(12):1365-75. doi: 10.1097/00004647-199912000-00010
- 31. Loubinoux, I., Pariente, J., Boulanouar, K., Carel, C., Manelfe, C., Rascol, O., Celsis, P., Chollet, F. (2002a). A single dose of the serotonin neurotransmission agonist paroxetine enhances motor output: double-blind, placebo-controlled, fMRI study in healthy subjects. *Neuroimage*, *15*(1), 26-36. doi:10.1006/nimg.2001.0957.
- 32. Loubinoux, I., Pariente. J., Rascol, O., Celsis, P., Chollet, F. (2002b). Selective serotonin reuptake inhibitor paroxetine modulates motor behavior through practice. A double-blind, placebo-controlled, multi-dose study in healthy subjects. *Neuropsychologia*. 40(11):1815-21.
- 33. Loubinoux, I., Tombari, D., Pariente, J., Gerdelat-Mas, A., Franceries, X., Cassol, E., Rascol, O., Pastor, J., Chollet, F. (2005). Modulation of behavior and cortical motor activity in healthy subjects by a chronic administration of a serotonin enhancer. *Neuroimage*. 27(2):299-313. doi:10.1016/j.neuroimage.2004.12.023
- 34. Kraglund, KL., Mortensen, JK., Damsbo, AG., Modrau, B., Simonsen, SA., Iversen, HK., Madsen, M., Grove, EL., Johnsen, SP., Andersen, G. (2018). Neuroregeneration and

- Vascular Protection by Citalopram in Acute Ischemic Stroke (TALOS). *Stroke*. 49(11):2568-2576. doi:10.1161/STROKEAHA.117.020067.
- 35. FOCUS Trial Collaboration. (2019). Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. *Lancet*. 393(10168):265-274. doi: 10.1016/S0140-6736(18)32823-X.
- 36. van der Worp, BH. (2019). Fluoxetine and recovery after stroke. *Lancet*. 393(10168):206-207. doi: 10.1016/S0140-6736(18)32983-0.
- 37. Klein, N., Sacher, J., Geiss-Granadia, T., Attarbaschi, T., Mossaheb, N., Lanzenberger, R., Pötzi, C., Holik, A., Spindelegger, C., Asenbaum, S., Dudczak, R., Tauscher, J., Kasper S. (2006). In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram. *Psychopharmacology (Berl)*. 188(3):263-72. doi:10.1007/s00213-006-0486-0.
- 38. Kasper, S., Spadone C., Verpillat P., Angst J. (2006). Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis. *Int Clin Psychopharmacol.* 21(2):105-10.
- 39. Sanchez, C., Reines, EH., Montgomery, SA. (2014). A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike? *Int Clin Psychopharmacol*. 29(4):185-96. doi: 10.1097/YIC.000000000000023.
- Gryga, M., Taubert, M., Dukart, J., Vollmann, H., Conde, V., Sehm, B., Villringer, A., Ragert,
   P. (2012). Bidirectional gray matter changes after complex motor skill learning. *Front Syst Neurosci*, 6:37. doi:10.3389/fnsys.2012.00037
- 41. Pasqualetti G., Gori G., Blandizzi C., Del Tacca, M. (2010). Healthy volunteers and early phases of clinical experimentation. *Eur J Clin Pharmacol*.;66(7):647-53. doi: 10.1007/s00228-010-0827-0.
- 42. Karakunnel, JJ., Bui, N., Palaniappan, L., Schmidt, KT., Mahaffey, KW., Morrison, B., Figg., WD., Kummar, S. (2018). Reviewing the role of healthy volunteer studies in drug development. *J Transl Med.* 4;16(1):336. doi: 10.1186/s12967-018-1710-5.
- 43. van Dyck, CH., Malison, RT., Seibyl, JP., Laruelle, M., Klumpp, H., Zoghbi, SS., Baldwin, RM., Innis, RB. (2000) Age-related decline in central serotonin transporter availability with [(123)I]beta-CIT SPECT. Neurobiol Aging. 21(4):497-501. doi: 10.1016/s0197-4580(00)00152-4.
- 44. Rao, N. (2007). The Clinical Pharmacokinetics of Escitalopram. *Clinical Pharmacokinetics* 46(4):281-90. DOI: 10.2165/00003088-200746040-00002.
- 45. Hardwick, RM., Rottschy, C., Miall, RC., Eickhoff, SB. (2013). A quantitative meta-analysis and review of motor learning in the human brain. *Neuroimage*. 15; 67:283-97. doi: 10.1016/j.neuroimage.2012.11.020.


- 46. Owens, MJ., Knight, DL., Nemeroff, CB. (2001). Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. *Biol Psychiatry*. 50(5):345-50. doi: 10.1016/s0006-3223(01)01145-3
- 47. Baird, JF., Gaughan, ME., Saffer, HM., Sarzynski, MA., Herter, TM., Fritz, SL., den Ouden, DB., Stewart, J.C. (2018). The effect of energy-matched exercise intensity on brain-derived neurotrophic factor and motor learning. *Neurobiol Learn Mem.* 156:33-44. doi: 10.1016/j.nlm.2018.10.008.
- 48. Grégoire, CA., Berryman, N., St-Onge, F., Vu, TTM., Bosquet, L., Arbour, N., Bherer, L. (2019). Gross Motor Skills Training Leads to Increased Brain-Derived Neurotrophic Factor Levels in Healthy Older Adults: A Pilot Study. *Front Physiol.* 10: 410. doi:10.3389/fphys.2019.00410.
- 49. Wymbs, FN., & Grafton, ST. (2014). The Human Motor System Supports Sequence-Specific Representations over Multiple Training-Dependent Timescales. *Cerebral Cortex*, 25(11) 4213–4225, doi: https://doi.org/10.1093/cercor/bhu144
- 50. Penhune, VB., Steele, CJ. (2012). Parallel contributions of cerebellar, striatal and M1 mechanisms to motor sequence learning. *Behav Brain Res.* 15;226(2):579-91. doi: 10.1016/j.bbr.2011.09.044.
- 51. Toni, I., Krams, M., Turner, R., Passingham, RE. (1998). The time course of changes during motor sequence learning: a whole-brain fMRI study. *Neuroimage*. 8(1):50-61. doi:https://doi.org/10.1006/nimg.1998.0349
- 52. Luft, AR., Buitrago, MM. (2005). Stages of motor skill learning. *Mol Neurobiol* 32(3):205-16. doi:10.1385/MN:32:3:205.
- 53. Karni, A., Meyer, G., Rey-Hipolito, C., Jezzard, P., Adams, MM., Turner. R., Ungerleider, LG. (1998). The acquisition of skilled motor performance: fast and slow experience-driven changes in primary motor cortex. *PNAS*;3;95(3):861-8. doi: 10.1073/pnas.95.3.861.
- 54. Hotermans, C., Peigneux, P., Maertens de Noordhout, A., Moonen, G., Maquet, P. (2006). Early boost and slow consolidation in motor skill learning. *Learn Mem.*;13(5):580-3. doi:10.1101/lm.239406
- 55. Poldrack, RA., Sabb, FW., Foerde, K., Tom, SM., Asarnow, RF., Bookheimer, SY., Knowlton, BJ. (2005). The neural correlates of motor skill automaticity. *J Neurosci*. 25(22):5356-64. doi: https://doi.org/10.1523/JNEUROSCI.3880-04.2005
- 56. Yang, J. (2015). The influence of motor expertise on the brain activity of motor task performance: A meta-analysis of functional magnetic resonance imaging studies. *Cogn Affect Behav Neurosci.* 15(2):381-94. doi: 10.3758/s13415-014-0329-0.
- 57. Schneider CL, Majewska AK, Busza A, Williams ZR, Mahon BZ, Sahin B. (2019). Selective serotonin reuptake inhibitors for functional recovery after stroke: Similarities with the critical period and the role of experience-dependent plasticity. *J Neurol*. 1-7. doi: 10.1007/s00415-019-09480-0

- 58. Stagg, CJ., Bachtiar, V., Johansen-Berg, H. (2011). The role of GABA in human motor learning. *Curr Biol.* 21(6):480-4. doi: 10.1016/j.cub.2011.01.069.
- 59. Stagg, CJ., Bachtiar, V., Amadi, U., Gudberg, CA., Ilie, AS., Sampaio-Baptista, C., O'Shea, J., Woolrich, M., Smith, SM., Filippini, N., Near, J., Johansen-Berg H. (2014). Local GABA concentration is related to network-level resting functional connectivity. *Elife*. 25;3:e01465. doi: 10.7554/eLife.01465.
- 60. Chen, Z., Silva, AC., Yang, J., Shen, J. (2005). Elevated endogenous GABA level correlates with decreased fMRI signals in the rat brain during acute inhibition of GABA transaminase. *J Neurosci Res.* 79(3):383-91.
- 61. Bhagwagar, Z., Wylezinska, M., Taylor, M., Jezzard, P., Matthews, PM., Cowen, PJ. (2004). Increased brain GABA concentrations following acute administration of a selective serotonin reuptake inhibitor. *Am J Psychiatry*. 161(2):368-70. doi: 10.1176/appi.ajp.161.2.368
- 62. El Mansari, M., Sánchez, C., Chouvet, G., Renaud, B., Haddjeri, N. (2005). Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission: an in vivo electrophysiological study in rat brain. *Neuropsychopharmacology*. 30(7):1269-77. doi:10.1038/sj.npp.1300686
- 63. Lladó-Pelfort, L., Santana, N., Ghisi, V., Artigas, F., Celada, P. (2012). 5-HT1A receptor agonists enhance pyramidal cell firing in prefrontal cortex through a preferential action on GABA interneurons. *Cereb Cortex*. 22(7):1487-97. doi: 10.1093/cercor/bhr220.
- 64. Karim, HT., Huppert, TJ., Erickson, KI., Wollam, ME., Sparto, PJ., Sejdić, E., Van Swearingen, JM. (2017). Motor sequence learning-induced neural efficiency in functional brain connectivity. *Behav Brain Res.* 15;319:87-95. doi: 10.1016/j.bbr.2016.11.021.
- 65. Mushiake, H., Inase, M., Tanji, J. (1991). Neuronal activity in the primate premotor, supplementary, and precentral motor cortex during visually guided and internally determined sequential movements. *J Neurophysiol*;66(3):705-18.
- 66. Halsband, U., Ito, N., Tanji, J., Freund, HJ. (1993). The role of premotor cortex and the supplementary motor area in the temporal control of movement in man. *Brain*;116 (Pt 1):243-66. doi:10.1093/brain/116.1.243.
- 67. Kalaska, JF., Crammond, DJ. (1995). Deciding not to GO: neuronal correlates of response selection in a GO/NOGO task in primate premotor and parietal cortex. *Cereb Cortex.*;5(5):410-28. doi:10.1093/cercor/5.5.410.
- 68. Bianchini, F., Verde, P., Colangeli, S., Boccia, M., Strollo, F., Guariglia, C., Bizzarro, G., Piccardi, L. (2018). Effects of oral contraceptives and natural menstrual cycling on environmental learning. *BMC Womens Health*. 18(1):179. doi: 10.1186/s12905-018-0671-4.
- 69. Henry, ME., Lauriat, TL., Lowen, SB., Churchill, JH., Hodgkinson, CA., Goldman, D., Renshaw, PF. (2013). Effects of citalopram and escitalopram on fMRI response to

- affective stimuli in healthy volunteers selected by serotonin transporter genotype. *Psychiatry Res.* 213(3): 217–224. doi:10.1016/j.pscychresns.2013.05.008.
- 70. Finnema, SJ., Nabulsi, NB., Eid, T., Detyniecki, K., Lin, SF., Chen, MK., Dhaher, R., Matuskey, D., Baum, E., Holden, D., Spencer, DD., Mercier, J., Hannestad, J. Huang, Y., Carson, RE. Imaging synaptic density in the living human brain. *Sci Transl Med*. 8(348):348ra96. doi: 10.1126/scitranslmed.aaf6667.
- 71. Chen, MK., Mecca, AP., Naganawa, M., Finnema, SJ., Toyonaga, T., Lin, SF., Najafzadeh, S., Ropchan, J., Lu, Y., McDonald, JW., Michalak, HR., Nabulsi, NB., Arnsten, AFT., Huang, Y., Carson, RE, van Dyck, CH. (2018). Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging. *JAMA Neurol.* 75(10):1215-1224. doi: 10.1001/jamaneurol.2018.1836.
- 72. Faul, F., Erdfelder, E., Lang, AG, Buchner A. (2007). G\*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. *Behav Res Methods*. 39(2):175-91. doi:10.3758/bf03193146.
- 73. Hampson, E. & Kimura D. (1988). Reciprocal effects of hormonal fluctuations on human motor and perceptual-spatial skills. *Behav Neurosci*. 102(3):456-9. doi:10.1037//0735-7044.102.3.456
- 74. Barth, C., Villringer, A., Sacher, J. (2015). Sex hormones affect neurotransmitters and shape the adult female brain during hormonal transition periods. *Front Neurosci.* 9:37. doi: 10.3389/fnins.2015.00037.
- 75. LeGates, T., Kvarta, MD., Thompson, SM. (2019). Sex differences in antidepressant efficacy. *Neuropsychopharmacology*;44(1):140-154. doi: 10.1038/s41386-018-0156-z.
- Uher, R., Farmer, A., Henigsberg, N., Rietschel, M., Mors, O., Maier, W., Kozel, D., Hauser, J., Souery, D., Placentino, A., Strohmaier, J., Perroud, N., Zobel, A., Dernovsek, MZ., Larsen, E.R., Kalember, A., Rajewska-Rager, P., Giovannini, M., McGuffin, P., Aitchison, KJ. (2009).Adverse antidepressants. Br J Psychiatry. 195(3):202-10. doi: 10.1192/bjp.bp.108.061960.
- 77. R Core Team (2013). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.
- 78. Iglewicz, B., Banerjee, S. (2001). A simple univariate outlier identification procedure. Proceedings of the Annual Meeting of the American Statistical Association.
- 79. Mugler, JP., 3rd, Brookeman, J.R. (1990). Three-dimensional magnetization-prepared rapid gradient-echo imaging (3D MP RAGE). *Magn Reson Med*;15(1):152-157. doi: 10.1002/mrm.1910150117.
- 80. Streitbürger, DP., Pampel, A., Krueger, G., Lepsien, J., Schroeter, ML., Mueller, K., Möller, HE. (2014). Impact of image acquisition on voxel-based-morphometry investigations

- of age-related structural brain changes. *Neuroimage*. 15; 87:170-82. doi:10.1016/j.neuroimage.2013.10.051.
- 81. Holiga, Š., Mueller, K., Möller, HE., Sieger, T., Schroeter, ML., Vymazal, J. (2013). Motor matters: tackling heterogeneity of Parkinson's disease in functional MRI studies. *PLoS One*. 2013;8:e56133. doi.org/10.1371/journal.pone.0056133.

## (i) Supplementary Methods:



**Supplementary Figure 1.** Overview of study work-flow: This flow chart details the screening, inclusion, randomization, and exclusion procedure. Six participants did not complete the study protocol due to self-reported adverse effects (Placebo = 2/escitalopram = 4). Two participants who completed the protocol (Placebo = 1, SSRI = 1) were excluded due to excess head movement as calculated by framewise displacement (>3SD outside the mean), the presence of structural (placebo n=1) and functional (escitalopram n=1) image artifacts, and a pre-analytical error in plasma acquisition (n=1\*). \*Refers to the same participant excluded from both behavioral and fMRI analyses.

# (ii) Supplementary Results

Supplementary Table 1. Mean functional brain responses at baseline, single dose, and steady state for the escitalopram group. Results of a one-sample t-test of the escitalopram group, revealing mean activation clusters. Results significant at p<0.001 cluster forming threshold corrected with p<0.05 FWE.

Brain Region	<i>p</i> (FWE-corr)	Cluster Size	T	Z	MNI(x,y,z)
Baseline					
Right Paracentral Lobule	< 0.001	2774	6.42	4.99	9, -43, 74
			6.27	4.91	18, 2, 59
			6.18	4.87	-9, -49, 68
Right Thalamus	0.012	169	6.39	4.98	12, -25, 17
-			5.6	4.55	21, -34, 14
			4	3.53	27, -49, 2
Left Cerebellum	< 0.001	437	5.72	4.62	-42, -55, -34
			5.14	4.27	-36, -58, -52
			4.92	4.14	-33, -67, -49
Right Middle Temporal Gyrus	< 0.001	478	5.68	4.6	48, -43, 5
•			4.89	4.12	51, -46, 26
			4.81	4.07	51, -28, -4
Right Cerebellum	0.007	193	4.88	4.12	30, -40, -40
-			4.53	3.89	30, -58, -34
			4.47	3.85	36, -52, -52
Single Dose					
Left Premotor Cortex	< 0.001	14076	9.93	6.45	-24, 2, 62
			9.84	6.42	6, -52, 56
			9.62	6.34	-9, -49, 62
Right Cerebellum	< 0.001	336	6.18	4.87	30, -67, -25
-			6.05	4.8	36, -52, -49
			5.37	4.41	39, -58, -28
Steady State					
Right Postcentral Gyrus	< 0.001	530	6.93	5.25	6, -49, 68
			6.05	4.8	-12, -49, 71
			4.54	3.9	-18, -64, 59
Right Middle Frontal Gyrus	0.031	137	5.88	4.71	30, 2, 65
-			5.49	4.49	24, -1, 71
			4.35	3.77	-6, -4, 77
Left Cerebellum	0.001	310	5.78	4.65	-36, -49, -37
			5.38	4.42	-39, -58, -31
			4.86	4.11	-33, -70, -19

Supplementary Table 2. Mean functional brain responses at baseline, single dose, and steady state for the placebo group. Results of a one-sample t-test of the placebo group, revealing mean activation clusters. Results significant at p<0.001 cluster forming threshold corrected with p<0.05 FWE.

Brain Region	<i>p</i> (FWE-corr)	Cluster Size	T	Z	MNI(x,y,z)
Baseline					
Left Cerebellum	< 0.001	8893	9.74	6.49	-36, -55, -49
			9.08	6.25	-24, -1, 65
			8.43	5.99	6, -52, 65
Right Cerebellum	0.001	198	7.05	5.37	30, -64, -52
			6.76	5.23	33, -52, -52
			6.57	5.13	27, -46, -46
Right Superior Temporal Gyrus	< 0.001	1007	6.95	5.32	48, -28, 2
			6.86	5.28	51, -34, 8
			6.29	4.99	48, -37, 29
Single Dose					
Left Supp. Motor Area	< 0.001	2646	7.82	5.73	-6, -1, 65
			6.63	5.16	24, 2, 65
			6.59	5.14	-24, 2, 68
Left Precuneus	< 0.001	1010	7.52	5.59	-9, -58, 59
			6.96	5.33	6, -46, 74
			6.47	5.08	9, -52, 68
Right Cerebellum	0.03	102	7.51	5.59	30, -64, -49
			4.77	4.08	36, -49, -49
			4.48	3.89	30, -43, -46
Left Cerebellum	< 0.001	363	6.18	4.93	-39, -58, -31
			5.39	4.48	-30, -67, -25
			5.17	4.34	-36, -55, -43
Right Cerebellum	0.009	141	5.77	4.7	33, -64, -28
C			4.43	3.86	36, -49, -37
			3.57	3.23	51, -64, -28
Right Superior Temporal Gyrus	0.001	244	5.72	4.67	60, -40, 23
- J			5.05	4.26	48, -40, 2
			3.62	3.27	48 ,-31 ,-1
Steady State					
Left Postcentral Gyrus	< 0.001	532	6.3	4.99	-9, -52, 65
			5.91	4.77	15, -61, 65
			5.26	4.39	-12, -61, 53
Left Premotor Cortex	0.001	251	6.21	4.94	-21, -1, 59
			5.6	4.6	-18, -1, 74
			4.51	3.91	-3, 5, 65
Right Middle Frontal Gyrus	0.007	168	5.75	4.68	30, 2, 65
<i>J</i> :			5.1	4.29	24, 2, 50
			4.51	3.91	18, 8, 62

# Supplementary Table 3. Significant correlations of brain and behavior – Escitalopram Group: Brain regions showing significant positive correlations between decreases in the learning contrast and improvements in lag learning-simple scores (LLSS) in the escitalopram group (n=29), KE=cluster size, T=t-values, Z=z-values, MNI(x,y,z)=MNI peak coordinates.

Brain Region	<i>p</i> (FWE-corr)	Cluster Size	T	Z	MNI (x,y,z)
Left Premotor Cortex	< 0.001	368	6.37	5.15	-18, -4, 56
			5.16	4.47	-18, 14, 53
			5.43	4.45	-9, 11, 68
Left Middle Temporal					
Gyrus	< 0.001	373	5.70	4.61	-45, -64, -1
			5.13	4.27	-42, -79, 20
			4.69	4.21	-42, -55, 11
Left Middle Temporal	-0.001	207	5 5 5	4.50	E1
Gyrus	< 0.001	307	5.55	4.52	51, -55, -7
			4.86	4.11	39, -67, 26
			4.56	3.91	39, -55, 11
Left Postcentral Gyrus	< 0.001	346	5.43	4.45	-12, -52, 59
			5.03	4.21	-6, -58, 65
			4.53	3.89	-15, -61, 53
Right Precentral Gyrus	0.032	83	5.33	4.39	-54, 8, 32
			4.78	4.05	-54, 2, 38
			4.42	3.82	-42, -1, 26
Left Superior Frontal Gyrus	0.002	160	5.09	4.25	-12, -19, 41
			4.72	4.02	-6, -25, 53
			4.29	3.73	-12, -22, 59
Left Middle Frontal Gyrus	< 0.001	338	4.86	4.11	-30, 44, 32
			4.62	3.95	-27, 53, 20
			4:60	3.94	-6, 41, 26
Left Thalamus	0.001	166	4.78	4.05	-18, -13, 14
			4.18	3.66	-27, -34, -4
			4.14	3.62	-18, -34, 19
Left Superior Parietal					· · · · · · · ·
Lobule	0.048	74	4.78	4.05	-42, -43, 56
			3.98	3.51	-33, -43, 32
			3.78	3.37	-39, -46, 41

Supplementary Table 4. Significant correlations of cortical motor response during sequence specific learning with drug plasma levels – Escitalopram Group: Brain regions showing significant negative correlations between decreases in the learning contrast and increases in escitalopram plasma levels, KE=cluster size, T=t-values, Z=z-values, MNI(x,y,z)=MNI peak coordinates.

Brain Region	p(FWE-corr)	Cluster Size	T	Z	MNI (x,y,z)
Left Supramarginal Gyrus	0.002	164	5.87	4.70	-33, -40, 32
			5.15	4.29	-33, -43, 41
			4.26	3.71	-45, -40, 50
Right Posterior					
Somatosensory Cortex	< 0.001	311	5.5	4.49	21, -55, 44
			5.31	4.38	33, -55, 26
			5.2	4.31	18, -61, 50
Left Premotor Cortex	< 0.001	198	4.9	4.13	-9, 11, 68
			4.74	4.03	-21, -4, 68
			4.69	4.00	-18, -4, 56